Two University of Kentucky Markey Cancer Center researchers have each received a Research Scholar Grant from the American Cancer Society (ACS), securing a combined $1.9 million to fund laboratory studies that may lead to new or more effective treatments for patients with few options.

Stage 2 prostate adenocarcinoma is localized, with a nearly 100%, five-year relative survival rate. Diagnosis uses the TNM system, PSA levels and Gleason score to determine cancer stage and risk. Treatment options include radical prostatectomy, external ...